Urology
Volume 69, Issue 3 , Pages 541-546 , March 2007

Intermediate-Risk Localized Prostate Cancer in the PSA Era: Radiotherapeutic Alternatives

  • Vinai Gondi

      Affiliations

    • Department of Radiation Oncology, Columbia University College of Physicians and Surgeons, New York, New York
    • ,
  • Israel Deutsch

      Affiliations

    • Department of Radiation Oncology, Columbia University College of Physicians and Surgeons, New York, New York
    • ,
  • Mahesh Mansukhani

      Affiliations

    • Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York
    • ,
  • Kathleen M. O’Toole

      Affiliations

    • Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York
    • ,
  • Jinesh N. Shah

      Affiliations

    • Department of Radiation Oncology, Columbia University College of Physicians and Surgeons, New York, New York
    • ,
  • Peter B. Schiff

      Affiliations

    • Department of Radiation Oncology, Columbia University College of Physicians and Surgeons, New York, New York
    • ,
  • Aaron E. Katz

      Affiliations

    • Department of Urology, Columbia University College of Physicians and Surgeons, New York, New York
    • ,
  • Mitchell C. Benson

      Affiliations

    • Department of Urology, Columbia University College of Physicians and Surgeons, New York, New York
    • ,
  • Erik T. Goluboff

      Affiliations

    • Department of Urology, Columbia University College of Physicians and Surgeons, New York, New York
    • ,
  • Ronald D. Ennis

      Affiliations

    • Department of Radiation Oncology, Columbia University College of Physicians and Surgeons, New York, New York
    • Corresponding Author InformationReprint requests: Ronald D. Ennis, M.D., Department of Radiation Oncology, St-Luke’s-Roosevelt Hospital-Roosevelt Division, Continuum Health Partners, 1000 Tenth Avenue, Lower Level, New York, NY 10019.

Received 8 May 2006 ,Accepted 13 December 2006.

References 

  1. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95:281–286
  2. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external beam radiotherapy. J Clin Oncol. 2002;20:3376–3385
  3. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >=72 Gy, permanent seed implantation, or combined seed/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25–33
  4. Stokes SH. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys. 2000;47:129–136
  5. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881
  6. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57:915–928
  7. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  8. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002;360:103–106
  9. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  10. Pilepich MV, Krall JM, Al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995;45:616–623
  11. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252
  12. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol. 1997;15:1013–1021
  13. Anderson PR, Hanlon AL, Movsas B, et al. Prostate cancer patient subsets showing improved BNED control with adjuvant androgen deprivation. Int J Radiat Oncol Biol Phys. 1997;39:1025–1030
  14. D’Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–827
  15. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005;23:1192–1199
  16. American Society for Therapeutic Radiology and Oncology. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  17. Ennis RD, Malyszko BK, Heitjan DF, et al. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:511–517
  18. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based in clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929–943
  19. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  20. Jhaveri FM, Klein EA, Kupelian PA, et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol. 1999;17:3167–3172
  21. Kupelian PA, Buchsbaum JC, Elshaikh MA, et al. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome. Int J Radiat Oncol Biol Phys. 2003;57:629–634
  22. Albertsen PC, Hanley JA, Barrow GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97:1248–1253
  23. Beahrs OH, Henson DE, Hutter RVP, et al. In: Manual for Staging of Cancer. 4th ed.. Philadelphia: JB Lippincott; 1992;p. 181–186
  24. Gewanter RM, Wuu C-S, Laguna JL, et al. Intraoperative preplanning for transperineal ultrasound-guided permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;48:377–380
  25. Pickles T, Kim-Sing C, Morris J, et al. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys. 2003;57:11–18
  26. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Force Group No. 43. Med Phys. 1995;22:208–234
  27. Williamson JF, Coursey BM, DeWerd LA, et al. Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription. Med Phys. 2000;27:634–642
  28. Beyer D, Nath R, Butler W, et al. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. Int J Radiat Oncol Biol Phys. 2000;47:273–275
  29. Lee PC, Moran BJ. 125 Gy or 135 Gy? (Comments on the American Brachytherapy Society article by Beyer et al). Int J Radiat Oncol Biol Phys. 2001;49:897–898
  30. Michalski JM, Williamson JF. In regard to Beyer, Nath and Butler et al. Int J Radiat Oncol Biol Phys. 2001;49:900

PII: S0090-4295(06)02639-2

doi: 10.1016/j.urology.2006.12.015

Urology
Volume 69, Issue 3 , Pages 541-546 , March 2007

Article Tools

* Image Usage & Resolution